Accessibility Menu

Omega Diagnostics Group Plc(LSE) ODX

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-95%
5 Year-97%
1 Year-53%
1 Month+0%
N/A
Omega Diagnostics Group Plc last closing stock price
MetricPriceDate
Last closeGBX 1.752026-07-30
Omega Diagnostics Group Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%GBX 1.752026-07-23
1 month+0%GBX 1.752026-06-30
3 month-14.63%GBX 2.052026-05-01
Year to date-10.26%GBX 1.952025-12-31
1 year-53.33%GBX 3.752025-07-30
3 year-32.69%GBX 2.602023-07-31
5 year-96.57%GBX 51.002021-07-30
Since inception-94.89%GBX 0.342007-08-16

Omega Diagnostics Group Plc Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£13.38M

Net Income (TTM)

-£3.57M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 22, 2023

ODX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Omega Diagnostics Group Plc

Cambridge Nutritional Sciences plc, established in 1987 and headquartered in London, UK, specializes in the development and supply of medical diagnostic products. The company focuses on food sensitivity testing, offering innovative kits and clinical analysis services to a diverse global clientele.

Products and Services
  • Foodprint branded kits for food sensitivity testing
  • Clinical analysis services for public and healthcare professionals
  • Food Detective consumer food test kits
Growth Outlook
  • Revenue increased to £3.86 million in Q2 2025
  • Gross profit margin improved to 61.8% in the latest quarter
  • Strong market presence across multiple continents enhances growth potential
Financial Highlights
  • Trailing twelve months (TTM) P/E ratio stands at 3.05
  • Current ratio of 4.25 indicates strong liquidity
  • Net income of £1.76 million reported in Q4 2024
Cambridge Nutritional Sciences plc operates in the medical instruments and supplies industry, focusing on food sensitivity testing. The company has shown resilience with a notable increase in revenue, reaching £3.86 million in the second quarter of 2025. The gross profit margin has also improved, indicating effective cost management and operational efficiency. The company's diverse product offerings, including the Foodprint kits and clinical analysis services, cater to a wide range of clients, from government entities to healthcare professionals. This broad client base supports sustained revenue growth and market expansion. Financially, the company demonstrates a strong liquidity position with a current ratio of 4.25, suggesting it can easily meet short-term obligations. The trailing twelve months P/E ratio of 3.05 reflects a potentially undervalued stock in comparison to industry peers. The recent net income of £1.76 million in Q4 2024 further underscores the company's profitability potential. Overall, Cambridge Nutritional Sciences plc presents a compelling opportunity for investors interested in the healthcare sector, particularly in the growing field of food sensitivity testing.
AI Generated • Jul 6, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

CEO

James Cooper

Website

www.omegadiagnostics.com

Headquarters

Alva, FK12 5DQ, GB

ODX Financials

Key Financial Metrics (TTM)

Gross Margin

60.93%

Operating Margin

-11.04%

Net Income Margin

16.94%

Return on Equity

12.15%

Return on Capital

-27.08%

Return on Assets

10.76%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

£7.44M

Operating Income

-£3.21M

EBITDA

-£4.11M

Operating Cash Flow

-£2.19M

Capital Expenditure

-£4.04M

Free Cash Flow

-£6.23M

Cash & ST Invst.

£5.12M

Total Debt

£74.00K

Omega Diagnostics Group Plc Performance Analysis

Omega Diagnostics Group Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-03-31GBP 8,539,000N/A
20232023-03-31GBP 7,546,000-11.6%
20242024-03-31GBP 9,774,00029.5%
20252025-03-31GBP 8,330,000-14.8%
Omega Diagnostics Group Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22021-09-30N/A
Q42022-03-31N/A
Q22022-09-30N/A
Q42023-03-31N/A
Omega Diagnostics Group Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-03-31GBP -0.06N/A
20232023-03-31GBP -0.02-73.1%
20242024-03-31GBP -0.00-91.6%
20252025-03-31GBP 0.01N/A
Omega Diagnostics Group Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22021-09-30N/A
Q42022-03-31N/A
Q22022-09-30N/A
Q42023-03-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2020YOY CHG

Revenue

£3.83M

+74.7%

Gross Profit

£1.31M

-6.8%

Gross Margin

34.29%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

91

N/A

Net Income

£1.31M

+437.8%

EBITDA

£1.01M

+166.9%

Quarterly Fundamentals

Name
Q4 2020YOY CHG

Total Cash

£5.12M

-12.2%

Total Debt

£74.00K

-97.4%

Accounts Receivable

£0.00

N/A

Inventory

£0.00

-100.0%

Long Term Debt

£19.00K

-99.2%

Short Term Debt

£55.00K

-85.5%

Return on Assets

10.76%

N/A

Return on Invested Capital

-8.00%

N/A

Free Cash Flow

-£4.44M

-663.8%

Operating Cash Flow

-£2.69M

-3021.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TCF.LTheracryf Plc
£0.00+0.00%
DEST.LDestiny Pharma plc
£0.03-25.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.13+0.11%
NVDANvidia
$195.04+0.03%
MSFTMicrosoft
$451.10+0.16%
NOKNokia
$9.09+0.08%

Questions About ODX

What is the current price of Omega Diagnostics Group Plc?

Omega Diagnostics Group Plc is trading at N/A per share.

What is the 52-week range for Omega Diagnostics Group Plc?

Over the past 52 weeks, Omega Diagnostics Group Plc has traded between N/A and N/A.

How much debt does Omega Diagnostics Group Plc have?

As of the most recent reporting period, Omega Diagnostics Group Plc reported total debt of £349.00K.

How much cash does Omega Diagnostics Group Plc have on hand?

Omega Diagnostics Group Plc reported £4.87M in cash and cash equivalents in its most recent financial results.

What is Omega Diagnostics Group Plc’s dividend yield?

Omega Diagnostics Group Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services